Christine Trueblood
Psychiatry · Kansas City, MONPI 1184871055
Payments from drug & device makers
Across 774 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$996
- Lundbeck LLC$588
- Sunovion Pharmaceuticals Inc.$583
- plus $5K from 29 others
What the payments were for
- Food & beverage$11,74899%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,847 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 15 | $27,799 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $24,620 |
| VraylarCariprazine Hcl | 12 | $16,859 |
| Lisdexamfetamine Dimesylate | 13 | $4,288 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 37 | $2,462 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 50 | $1,817 |
| Oxcarbazepine | 29 | $1,404 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 36 | $774 |
| Duloxetine Hcl | 38 | $618 |
| Quetiapine Fumarate | 44 | $546 |
| Bupropion XlBupropion Hcl | 31 | $429 |
| Clonazepam | 62 | $322 |
| Gabapentin | 27 | $307 |
| Aripiprazole | 21 | $293 |
| Lorazepam | 52 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $996 | $27,79915 claims |
| AbbVieVraylar | $2,351 | $16,85912 claims |
| Almatica Pharma LLCSertraline Hcl | $107 | $6720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Kansas City
- Brian BarashKansas City$857K
- Mark CannonKansas City$19K
- Syed KarimKansas City$17K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.